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Abstract: The recent development of high throughput methods of deoxyribonucleic acid (DNA) 
sequencing has made it possible to determine individual genome sequences and their specific 
variations. A region of particular interest is the protein-coding part of the genome, or exome, 
which is composed of gene exons. The principles of exome purification and sequencing will be 
described in this review, as well as analyses of the data generated. Results will be discussed in 
terms of their possible functional and clinical significance. The advantages and limitations of 
exome sequencing will be compared to those of other massive sequencing approaches such as 
whole-genome sequencing, ribonucleic acid sequencing or selected DNA sequencing. Exome 
sequencing has been used recently in the study of various diseases. Monogenic diseases with 
Mendelian inheritance are among these, but studies have also been carried out on genetic varia-
tions that represent risk factors for complex diseases. Cancer is another intensive area for exome 
sequencing studies. Several examples of the use of exome sequencing in the diagnosis, prognosis, 
and treatment of these diseases will be described. Finally, remaining challenges and some practical 
and ethical considerations for the clinical application of exome sequencing will be discussed.
Keywords: massively parallel sequencing, RNA sequencing, whole-genome sequencing, 
genetic variants, molecular diagnosis, pharmacogenomics, personalized medicine, NGS, SGS, 
SNP, SNV
Introduction
Numerous diseases have a genetic basis. Some are the consequence of an absence or 
dysfunction of a given protein due to mutations in the encoding gene. This is the case 
with diseases of Mendelian inheritance, such as Huntington’s disease, thalassemia, and 
approximately 1,000 other inherited rare diseases.1 Many diseases have a genetic basis, 
even if they are not exclusively due to the mutation of a single gene, and an increasing 
number of genetic variants and polymorphisms are being identified as risk factors for 
complex diseases.2 Cancer is a genetic disease caused by the mutation of one or more 
genes that either increase the risk of cancer (such as germ line mutations), or they 
promote cancer (oncogenes), or they impair the cellular mechanisms that control cell 
proliferation (suppressor genes), as occurs with somatic mutations.3
The identification of the genetic basis of these diseases has been a labor-intensive 
and challenging project, up until a few years ago. These projects often started with 
the identification of a genome region possibly involved in the transmission of the 
disease by genetic association studies.1 The analysis of large families with several 
affected members is usually required to define a genome region that is highly related 
to disease transmission. Generally, this region contains several genes that must be 
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sequenced to identify a gene mutation present in all the 
affected individuals and not in their healthy relatives, in 
the case of dominant inheritance. In the case of recessive 
transmission, the mutation should be present in both alleles 
of the affected members and in one, or none, of the alleles 
of the unaffected relatives.
Diagnosis of genetic diseases was, and in most cases still 
is, equally laborious. In the best-case scenario, the disease 
can originate in a mutation in only one gene. Diagnosis would 
require determining the nucleotide sequence of that gene only. 
Typically, the gene is amplified as several  fragments by poly-
merase chain reactions and the nucleotide sequence of each is 
determined. Often, the disease can be caused by mutations in 
any of several genes, and all of them must be amplified and 
sequenced in order to find the genetic origin of the disease in 
the affected patients. For example, in dyskeratosis congenita, 
mutations can be found in any of the genes dkc, tert, terc, 
NOP10, NH2, or TINF2, and the number of affected genes 
can be even larger since there is a fraction of patients in 
whom the causative mutation has not been identified.4,5 The 
nucleotide sequence of all these genes must be determined 
for the molecular diagnosis of each patient. We find several 
mutated genes in various types of cancers.3 Molecular diag-
nosis requires determining the nucleotide sequence of several 
of these genes. Currently, this is a laborious and expensive 
process that cannot be used for a large population of patients. 
In practice, only a few genes that are mutated in an important 
proportion of patients affected by some cancer types are 
sequenced for diagnosis and treatment.
Only in the last few years have techniques been developed 
for the simultaneous detection of multiple sequence variants 
in a given sample. Many of them are based on deoxyribo-
nucleic acid (DNA) microarray technology. In genotyping 
arrays, oligonucleotides containing the actively identified 
mutations related to a given disease are spotted on a slide. 
A patient’s DNA sample is added on top of the slide and 
the hybridizing oligonucleotides are identified. Millions 
of known mutations can be tested in a single microarray 
hybridization.6 Copy number variations can also be analyzed 
using DNA microarrays designed to detect the presence of 
DNA regions that are duplicated or deleted in the DNA of 
the patient.7 These techniques are frequently used in medical 
research and for clinical diagnosis.8
However, a major step in molecular medicine has 
been the recent development of massive sequencing tech-
nologies that allow the nucleotide sequence of a patient’s 
DNA to be  determined in a short period of time and at an 
 affordable price.9,10 These methodologies have been in use 
since 2005 and are based on the simultaneous determination 
of the nucleotide sequence of millions of DNA fragments. 
They have been named as second generation sequencing, 
next generation sequencing, deep sequencing, or massively 
parallel sequencing. Thousands of millions of nucleotide 
sequences are determined in no more than 2 weeks using 
these machines. As an example of the capacity of these new 
sequencing systems, note that the milestone sequencing of the 
first human genome, published in 2001,11 required the coor-
dinated work of 23 laboratories, which took 13 years, with a 
total cost of about US$3 billion. With the new methodologies, 
sequencing a human genome takes one laboratory and about 
2 weeks, with an approximated cost of US$4,000.
The availability of modern sequencing methodologies is 
producing the exponential growth of our knowledge about 
the human genome, variability among individuals, and the 
identification of genetic variants in diseases. For example, 
these methodologies are the foundation of an ongoing 
1000 Genomes Project,12 aimed at determining the complete 
nucleotide sequence of about 1,000 persons from different 
geographic and ethnical origins to determine the average 
sequence variation among individuals and to identify the 
most frequent polymorphisms.
Massive sequencing technologies are presently evolving at 
a fast pace. Smaller, faster machines are being developed, and 
new sequencing methods are being introduced. An important 
aim, for example, is to sequence a single DNA molecule from 
an individual cell.13,14 Aside from the technical challenges, 
advances are steadily decreasing the price of DNA sequencing 
so that the goal of sequencing an individual human genome 
for US$1,000 seems to be within reach in a few years. Pres-
ently, sequencing a whole human genome and analyzing all 
the sequence data generated is complex, expensive, and time 
consuming, and many studies are being carried out in a smaller 
part of the genome. In particular, much attention is currently 
being paid to sequencing the protein-coding region of the 
genome, which is known as the exome. Exome sequencing 
is far more affordable than whole-genome sequencing, and 
the possibilities, advantages, and limitations of this technique 
will be discussed in this review.
What is an exome?
Almost all human protein-coding genes have a  discontinuous 
structure. The protein-coding region is fragmented 
into  several pieces, called exons. Exons are connected 
by  nonprotein-coding DNA fragments, or introns, as 
 schematically shown in Figure 1. Genes are transcribed from 
the promoter region under the control of several regulatory 
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regions, which are present in different locations in relation 
to the gene, upstream, downstream, or even inside the gene. 
Transcription creates a primary transcript that contains exons 
and introns. Subsequent ribonucleic acid (RNA) splicing 
processes delete the introns and join the exons to generate 
the mature messenger RNA (mRNA) that contain only one 
continuous protein-coding region. Recent studies show that 
the primary transcripts of most genes can be spliced in sev-
eral ways, giving rise to various mature mRNAs containing 
specific combinations of exons, known as alternative splicing 
variants (Figure 1). These mRNAs code for protein isoforms 
that have some common regions, but that also differ from 
other ones, depending on the exons incorporated.15
Analysis of the human genome has shown that protein-
coding genes represent a small proportion of DNA, only about 
3%.16 Exons represent an even smaller fraction at 1% of the 
genome.16 A summary of this data is shown in Table 1. The 
human genome is composed of 3.3 × 109 base pairs (bp) and 
contains 20,078 protein-coding genes.17 Each gene is divided 
in an average number of eight exons, each about 170 bp long. 
All the exons as a whole contain about 3 × 107 bp. However, 
sequencing all the exons provides the same information 
about the amino acid sequence of the encoded proteins as 
sequencing the whole genome, with the exception of muta-
tions that alter mRNA splicing, as will be discussed in the 
Exome sequencing and data analysis section. This system of 
sequencing all the exons has been named exome sequencing 
and has become a valid method of detecting variations in the 
amino acid sequence of all human proteins.18 The very marked 
size difference makes exome sequencing much cheaper than 
genome sequencing, and this facilitates computational and 
functional analyses of the sequence data generated.
Exome capture techniques
The first and most critical step in exome sequencing is the 
 isolation or capture of the exons. The methods utilized are 
based on DNA hybridization. The analysis of the human 
genome has made the identification of all gene exons 
 possible, and it facilitates the design of oligonucleotide 
probes specific to each of them. The probes are used for 
purification of the exons from the DNA.19 Fragmentation 
of the DNA into pieces no bigger than 500 bp is the first 
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Figure 1 Schematic representation of gene structure and expression.
Notes: Protein-coding genes are composed of exons that contain protein-coding information (boxes), separated by noncoding introns (lines). Gray boxes indicate exon 
protein-coding regions and white boxes represent mRNA 5′ and 3′ un-translated regions. Genes are transcribed from the promoter regions, immediately upstream of 
exon 1. The transcription start site is indicated by an arrow. Gene expression is controlled by a number of TR regions that can be located upstream or downstream of the 
gene, at variable distances, or inside the gene (most frequently in introns). The mRNA stability and translation can be regulated by microRNA binding to specific sites in the 
3′ un-translated region (indicated by asterisks). Genes are transcribed into primary RNAs containing introns and exons. Subsequent splicing processes eliminate the introns 
to generate mature mRNAs. Alternative splicing processes can give rise to different mRNAs, depending on the exons that they contain (mRNA1, mRNA2), that code for 
different protein isoforms.
Abbreviations: TR, transcription regulatory region; RNA, ribonucleic acid; mRNA, messenger ribonucleic acid.
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step. The DNA is then hybridized to the exon-specific 
oligonucleotide probes and the hybridized fragments are 
purified. Hybridization can be performed in the liquid 
phase. In this case, oligonucleotides are labeled so that 
DNA–oligonucletide complexes can be separated from 
the bulk of nonhybridized DNA. In a common example, 
oligonucleotides are covalently bound to biotin so that 
DNA–oligonucleotide hybrids can be isolated using the 
biotin-binding molecule, streptavidin, coupled to magnetic 
beads. DNA fragments that do not contain exons will 
not bind to the streptavidin beads and can be efficiently 
removed after several washing steps. The fragments con-
taining exons, bound to the beads, can be recovered after 
dissociation of the DNA–oligonucleotide hybrids under 
low-ionic strength conditions. 
Exons can also be isolated by hybridization to a solid 
support where the exon-specific oligonucleotides have 
been spotted, as with DNA microarrays. In this case, the 
fragmented DNA is spread over the oligonucleotides to 
allow hybridization. Later, nonhybridized DNA is washed 
away and the exon-enriched DNA is eluted under low-ionic 
conditions.
Various commercial suppliers offer kits for exome isola-
tion using liquid phase hybridization protocols,  including 
Agilent Technologies (Santa Clara, CA, USA), Roche 
NimbelGen, Inc. (Madison, WI, USA), Illumina, Inc. (San 
Diego, CA, USA), and Life Technologies (Carlsbad, CA, 
USA). These kits allow for the isolation of over 90% of the 
exons present in the genome, with over 90% specificity at an 
approximate price of US$150 per exome. Several authors have 
compared these exome capture platforms,20–22 and the data 
obtained by Clark et al22 comparing the SureSelect Human 
All Exon 50 Mb (Agilent Technologies), Roche NimbleGen, 
Inc.’s SeqCap EZ Exome Library v2.0, and Illumina, Inc.’s 
TruSeq Exome Enrichment kits are summarized in Table 2. 
Some of the kits cover the untranslated regions of mRNA, in 
addition to the protein-coding regions, and this allows for the 
analysis of regulatory regions such as microRNA (miRNA) 
binding sites. The inclusion of 5′ untranslated regions also 
allows for the analysis of the proximal promoter regions.22 In 
addition, most of the kits cover up to 80% of the miRNA 
coding regions.21 Recently, improved kits have been developed 
by these and other suppliers so that the data shown in Table 2 
should be considered an indication only. It is important to 
note that exon purification is a critical step. Recovering 100% 
of the exons is difficult, and exons are frequently lost or 
underrepresented in the isolated exome. For example, if the 
exome of a patient is being analyzed and 10% of the exons 
are lost during purification, the probability of missing a rel-
evant mutation will be about 10% due to this technical error. 
Therefore, the use of highly efficient exon-capture procedures 
is of critical importance in exome sequencing.
Exome sequencing and data analysis
Exon-containing fragments are sequenced using any of the 
presently available massive sequencing equipment systems 
or technologies. As mentioned in the introduction, these 
platforms determine the nucleotide sequence of millions of 
DNA fragments simultaneously. The determined length of 
Table 1 General characteristics of the human genome and exome
Parameter Number/size
Genome size 3,300 millions of base pairs
Number of protein-coding genes 20,078
Number of exons 180,000
Medium exon size 170 base pairs
exome size 30 millions of base pairs
Table 2 Comparison of three major exome-capture platforms
Agilent Technologies’  
Sure Select Human All  
Exons 50 Mb
Roche NimbelGen, Inc.’s  
SeqCap EZ Exome Library v2.0
Illumina, Inc.’s TruSeq 
Exome Enrichment 
Region covered by the probes 51.5 Mb 44 Mb 61.9 Mb
Coverage of transcribed regions 97.38%–98.79%a 86.63%–98.63%a 93.31%–97.45%a
Coverage of mRNA untranscribed  
regions
12.04% 8.64% 97.84%
Efficiency based on 80 mega reads  
and 10× depthb
89.6% 96.8% 90.0%
Off-target enrichment 12.8% 9.3% 35.6%
Additional information Better coverage of the ensemble  
database
Higher probe density. Better  
miRNA coverage
Capture untranslated 
regions. Larger number 
of reads required
Notes: aComparison of the ensemble81 and RefSeq82 databases, respectively; bpercentage of the selected regions sequenced by each platform at least ten times after the analyses 
of 80 mega reads of the DNA sequence. Agilent Technologies (Santa Clara, CA, USA); Roche NimbelGen, inc. (Madison, wi, USA); illumina, inc. (San Diego, CA, USA).
Abbreviations: mRNA, messenger ribonucleic acid; miRNA, micro ribonucleic acid; DNA, deoxyribonucleic acid.
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the sequence of each fragment in exome sequencing is not 
long, typically between 35 bp and 100 bp. However, since 
the DNA was initially fragmented randomly, each individual 
nucleotide will be present in many overlapping fragments. 
Therefore, if a high enough number of sequences is obtained, 
even if short, every base will be independently sequenced in 
several DNA fragments. The number of times that each base 
is sequenced is called coverage or sequencing depth. The 
coverage is directly related to the quality and confidence of 
the nucleotide sequence generated. In general, coverage of 
20×−30× is considered necessary to obtain reliable results 
in exome sequencing.59 This sequencing depth means that 
a possible sequence variation would have been sequenced 
independently in 20–30 different DNA fragments.
Data analysis is the last step in exome-sequencing proj-
ects (Figure 2). As mentioned above, data from millions of 
sequences are generated, and their analyses require specific 
and complex computer programs and expertise.19,23 A pre-
liminary step is an analysis of the quality of the sequence 
generated. The accuracy of sequence reading at various 
sequence lengths, the average length of the reads, as well as 
other parameters, are tested. If the quality is good enough, 
each sequence is compared to a reference sequence, which 
is usually the last available version of the human genome 
sequence. Typically, over 80% of the sequences generated 
can be aligned with the reference genome.22 This step allows 
a small degree of nucleotide variation with respect to the 
reference genome. The next step in the analysis is to identify 
DNA isolation
Exon selection
Exon sequencing
Alignment to reference sequence
Identification of sequence variants
Data filtering
Identification of infrequent
or novel variants
Databases search
Presence of variants in
pathology driver genes
Diagnosis Prognosis
Genetic counseling Personalized treatment
Presence of variants in
genes previously related to
diseases by association studies
Figure 2 exome sequencing data analysis.
Notes: The steps required for exome isolation, sequencing, and data analysis are schematically represented. This process drives the identification of gene variants involved 
in the origin of the diseases (driver genes) or otherwise related to disease susceptibility, evolution, or pharmaceutical response. These data provide valuable information for 
diagnosis and prognosis, for genetic counseling, and for the design of personalized treatments.
Abbreviation: DNA, deoxyribonucleic acid. 
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sequence variations between the reference sequence and the 
exome sequence obtained in our study. The subsequent analy-
ses of these variants could provide the desired information 
on the medical problem under study.
Exome sequencing can detect several types of genetic 
variations. One of the most frequently found differences is 
a change of one nucleotide into another, for example, A for 
G (ATA codon to ATG). These variations are called single 
nucleotide variants (SNVs), although they are considered 
single nucleotide polymorphisms (SNPs) when their fre-
quency in the population is larger than 1%–5% and there is 
no strong effect on the risk of any disease. Most SNVs are 
silent, or also known as synonymous, because both sequence 
variants code for the same amino acid (for example, a varia-
tion of GCA to GCC, since both are alanine codons). Most 
of these polymorphisms do not represent any difference for 
the encoded protein, are not under evolutionary selection, 
and represent the most frequently found variations in the 
human exome. The exception are some silent mutations 
that affect splicing-regulatory signals, or even transcription 
regulatory sites, altering mRNA splicing or expression even 
if they do not change the encoded amino acids. In other cases, 
the nucleotide variation has a consequence in the encoded 
protein and these are nonsilent or nonsynonymous variants. 
These changes can result in variations in the encoded amino 
acid (for example, GAT to GAG changes aspartic acid to 
glutamic acid), and are called missense mutations. More 
drastic alterations are produced when the nucleotide variation 
creates a translation stop codon (for example, TGC to TGA 
changes a cysteine codon to a stop codon), which is called 
a nonsense mutation. There is also a type of SNV that can 
be detected by exome sequencing even if it does not affect 
the protein codons. Since exons are selected after random 
fragmentation of the DNA, they can also contain contiguous 
DNA regions, including neighboring intron sequences and 
even gene promoters if untranslated regions were captured.24 
Intron regions contain the regulatory signals required for 
mRNA splicing. SNVs in these regions can alter splicing 
in various ways.15 For example, the affected intron might be 
retained in the mature mRNA, or the contiguous exon might 
be spliced out (exon skipping). These alterations change the 
nucleotide sequence of the mature mRNA and, therefore, 
the encoded protein downstream from the SNV.25 Exome 
sequencing can also detect sequence variations due to small 
insertions or deletions (indels).22 These variations can result 
in a frame shift, except when they affect three or a multiple 
of three nucleotides. In that case, small deletions or insertions 
of amino acids would be produced.
Identification of causative  
mutations
The functional relevance of the sequence variants detected 
must be determined in the next data analysis step. Even if 
all humans are almost identical from a genetic point of view, 
the number of nucleotide sequence differences among indi-
viduals is considerable.26 This heterogeneity complicates the 
interpretation of the data obtained in individual sequencing 
projects. Some general data on individual sequence variations 
are shown in Table 3. When considering the whole genome, 
the number of sequence differences among individuals has 
been estimated at 4 × 106, according to the data obtained 
in the 1000 Genomes Project and smaller whole-genome 
sequencing projects.27 Exomes show a smaller, but still 
 considerable, number of sequence variations, numbering 
about 20,000–25,000 between any two unrelated individu-
als.27,28 Most of these genetic variations are silent, as discussed 
earlier. The number of nonsilent sequence differences among 
individuals has been estimated at 10,000. Most of these vari-
ants exist in the general population and are transmitted for 
generations. It has been estimated that less than one nonsilent 
SNV appears de novo in each individual.29
The data obtained in exome sequencing projects are fre-
quently filtered to identify all the SNPs that are present in other 
individuals and that are not, therefore, related to the  disease being 
studied.2,19,23 This process can be done by comparison with pub-
lic databases where the SNPs that are found in the sequencing 
projects are compiled. A caveat to be taken into account is that 
all large databases contain a number of proven mutations causing 
relatively frequent diseases. About 400–700 novel, and possibly 
relevant, SNVs remain after this filtering step (Table 3).28 The 
next challenge is to determine which of the SNVs that are not 
present in the global population, if any, are at the origin of the 
disease under study. Many of the differences observed will not be 
associated with any incidence of the disease, and these are known 
as passenger changes.23 In contrast, one or a few changes might 
have a causative role and they are called driver changes. The 
approach used to identify these driver changes will depend 
on the particular circumstances of the study. In diseases with 
a Mendelian pattern of inheritance, it is usually necessary to 
Table 3 Summary of the sequence variation among individuals
Parameter Number
Sequence variants in any genome 4 × 106
Sequence variants in any exome 20,000–25,000
Nonsilent variants 10,000
Filtered novel variants 400–700
De novo genome variants/individual ,1
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analyze a number of affected and nonaffected individuals to 
find gene variations that perfectly segregate with the disease. 
This comparison is more informative in large families with 
well characterized pedigrees. In the absence of sufficiently 
large affected families, the comparison of a number of unre-
lated patients and controls also allows for the identification 
of driver genes. Additional criteria are used to select possible 
SNVs related to the disease, including in silico algorithms, 
which predict the possible importance of the mutated amino 
acid based on evolutionary conservation, and on the predicted 
impact on the structure and function of the protein. The pre-
dicted function of the mutated protein and its tissue-specific 
expression pattern are also criteria used in selecting putative 
causative mutations.
Some examples of these types of studies will be provided 
in a later section. However, as more studies are being carried 
out, more gene variations are being identified as causative 
of inherited diseases, which makes it probable that some of 
the genes mutated in the patient would have already been 
described. These mutated genes can be found in the literature 
and in specialized databases such as the Online Mendelian 
Inheritance in Man database (http://www.omim.org). The 
possible relevance of the mutations found in various genes 
can also be searched in the Genome Ensemble page (http://
www.ensembl.org/) if they have been previously described.
Cancer is probably the most prevalent group of diseases 
with a genetic basis. Many studies have been directed to 
determine the driver genes for various types of cancer.30 The 
emergent group of cancer driver genes can be consulted in 
databases such as the Catalogue of Somatic Mutations In 
Cancer (COSMIC; http://cancer.sanger.ac.uk) or The Cancer 
Genome Atlas (http://cancergenome.nih.gov/). Several more 
detailed examples will be shown in the Examples of the 
clinical use of exome sequencing section.
Comparison of exome  
sequencing to other massive  
sequencing approaches
Genome sequencing
As mentioned in the Introduction, sequencing the whole human 
genome is becoming more and more affordable. Compared 
to exome sequencing, whole-genome sequencing is a much 
more complex alternative. The number of sequencing reactions 
that must be carried out is much higher, as are the numbers of 
nucleo tide sequence data generated. The computational analy-
sis is greatly increased. In addition, many more genetic variants 
are found, as shown in Table 3, which makes the identification 
of driver genes more difficult. However, genome sequencing 
provides a complete view of the genetic alterations present in 
the patient, including large genome reorganizations. However, 
short-read sequencing of a genome at moderate depth will miss 
structural variations, especially in low-complexity regions. 
This information is summarized in Table 4, which compares 
exome sequencing to other sequencing approaches.
As mentioned earlier, protein-coding genes only represent 
3% of the genome.16 Until recently, the rest of the genome 
was considered to be “bulk DNA” without much information 
value. However, recent studies have completely changed this 
Table 4 Comparison of massive sequencing techniques
Technique Properties Limitations
exome sequencing –  Detects genetic variations in all the protein-coding  
regions of the genome.
–  Detects nucleotide variations and small insertions and 
deletions.
–  exome size relatively small (1% of the genome size).
–  Genetic variations in nonprotein-coding regions,  
including gene expression regulatory regions, are 
not detected.
Genome sequencing –  Detects all the genetic variations, including protein- 
coding and regulatory regions.
–  Detects nucleotide variations and genome reorganizations 
such as deletions, duplications, inversions, or  
translocations.
–  The large size of the human genome makes genome 
sequencing expensive and the analyses of the data  
generated long and complex.
RNA sequencing –  Detects genetic variations in protein-coding regions.
–  RNA expression levels can be determined.
–  Detects RNA splicing variants.
–  The size of the transcriptome is much smaller than that 
of the genome.
–  The analysis is restricted to the genes expressed in 
the tissue or cell type analyzed.
–  Genetic variations in untranscribed regions are not 
detected.
Selected-DNA  
sequencing
–  Detects genetic variants in a set of predetermined genes.
–  A relatively small amount of sequencing and data  
analysis is required.
–  Can be easily applied to a large number of patients.
–  Only the preselected DNA regions are analyzed.
Abbreviations: RNA, ribonucleic acid; DNA, deoxyribonucleic acid.
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point of view. A large genome-wide project is studying the 
function of all the regions of the genome, the Encyclopedia of 
DNA Elements (ENCODE) project.31 The presently  available 
results show that over 70% of the genome is transcribed. 
Many of the transcripts generated do not code for proteins, 
but they seem to have a regulatory role in gene expression. 
Among them are the already known miRNAs, which regulate 
mRNA stability and translation (Figure 1), but also over 
20,000 long noncoding RNAs that regulate transcription. In 
addition, many DNA regions that regulate gene expression 
have been identified, including many previously unknown 
promoter and transcription regulatory regions (Figure 1). 
This information is of clinical relevance because mutations 
in regulatory regions can affect the expression of specific 
genes and can have pathological results. In fact, a large 
proportion of genome-wide association studies have related 
DNA regions, where no protein-coding mutations have been 
found, with pathological conditions.32 The data generated 
in the ENCODE project have allowed for the revision of 
some cases, which found that mutations in gene-expression 
regulatory regions are responsible for the disease.31,32 Also, 
in a recent example, Weedon et al33 reported that mutations 
in a transcription regulatory region of the PTF1A gene 
cause isolated pancreas agenesis. Mutations in regulatory 
regions cannot be detected by exome sequencing since they 
do not affect the encoded protein, but instead its expression. 
 Therefore, whole-genome sequencing provides more infor-
mation than exome sequencing at the expense of increased 
complexity and economic cost.
RNA sequencing
RNA sequencing techniques consist of the conversion 
of RNA populations to complementary DNA (cDNA) by 
reverse transcription and their subsequent sequencing.34,35 In 
the case of mRNA sequencing, the complete population of 
mRNAs expressed in a cell line or tissue sample (known as 
transcriptome) are converted to cDNA and sequenced. The 
process of mRNA sequencing provides information about 
the nucleotide sequence of the genes that are being tran-
scribed in the sample analyzed and, therefore, on the amino 
acid sequence of the corresponding proteins. In addition, 
the number of sequences generated for each mRNA can be 
estimated and is proportional to its abundance. Therefore, 
gene expression levels can be determined and compared to 
those of other samples, including possible control samples 
(Table 4). Another specific advantage of mRNA sequencing 
is that it allows the study of alternative splicing events.36,37 
As mentioned earlier, primary transcripts are often processed 
in multiple ways to give rise to mRNA that contain different 
exons (Figure 1). These mRNAs can be identified by mRNA 
sequencing and not by exome or genome sequencing, which 
determines the sequencing of the DNA being transcribed 
and not that of the mature transcript. Otherwise, mRNA and 
exome sequencing provide similar information about the 
protein-coding region of the genome. The difference is that 
exome sequencing includes all the genes and mRNA sequenc-
ing is restricted to the genes expressed in the sample analyzed. 
For example, a recent mRNA sequencing study of lympho-
blastoid cell lines from 462 individuals determined the coding 
sequence of about 13,000 genes out of the 20,078 human 
genes.38 In this example, about 7,000 genes were not stud-
ied because they were not expressed in lymphoblastoid cell 
lines. However, in those cases where the cell type or tissue 
affected by a given disease is well known, mRNA sequencing 
would be equivalent to exome sequencing for the study of 
driver mutations. Another characteristic of mRNA sequenc-
ing is that it allows for the detection of sequence variations 
produced by RNA editing.39 A number of mRNAs are pro-
cessed so that some nucleotides are changed, and adenosine 
to inosine changes are the most frequently  produced. These 
alterations are detected by mRNA sequencing, but whether 
they are produced by RNA editing or as a consequence of 
genomic variations cannot be determined unless both the 
mRNA and genomic sequences are compared.
Determining mRNA expression levels can be very conve-
nient in certain cases, since some diseases can be caused by 
the deregulated expression of one or more genes. Changes in 
expression levels can be very informative about the genetic 
origin of the disease. For example, alterations in the expression 
of one or more genes in a patient could indicate a dysfunction 
in the mechanisms that regulate their expression. This dys-
function could be due to mutations in the gene- transcription 
regulatory regions, as discussed in the genome sequencing 
section. It could also be due to alterations in the expression 
or structure of transcription regulatory factors.40 Changes 
in gene expression are frequently due to alterations in epi-
genetic mechanisms of gene expression regulation, such as 
DNA methylation, which cannot be detected by genome or 
exome sequencing.41 Methods for the study of whole-genome 
methylation that allow for the detailed study of this epigenetic 
information have been recently developed.42 Cancer is one of 
the diseases on which more studies in gene expression levels 
have been carried out. In an increasing number of cases, 
alterations in the expression of genes or a group of genes 
are related to a cancer diagnosis, prognosis, or a prediction 
of the response to anticancer drugs.43 These changes in gene 
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expression are being used as biomarkers. Many of these stud-
ies are available through the Cancer Genome Anatomy Project 
(http://cgap.nci.nih.gov) database.
A specific type of RNA sequencing project is aimed at 
determining the nucleotide sequence and expression levels of 
small regulatory RNAs (miRNAs). Small RNAs regulate the 
expression of other genes by determining the stability and/or 
translation of their mRNAs (Figure 1). Changes in patterns of 
miRNA expression can, therefore, have a marked impact on 
the protein expression profile of cells and tissues. Protocols 
have been developed for the purification and sequencing of 
the complete population of miRNAs of a given sample and 
to determine their expression levels.44 Most exon-capture 
platforms also include up to 80% of the known miRNA-
coding regions.21
Sequencing selected sets of genes
Some diseases have already been studied in such detail 
that most of the genes involved are known. This can be the 
case with diseases with a Mendelian pattern of inheritance, 
in which all the cases studied are due to mutations in any 
of a number of known genes. Other examples are some 
cancer types that are predominantly due to mutations in a 
reduced number of genes. In such cases, the more direct 
approach to characterize a patient’s sample would be to 
determine the sequence of the genes previously identified 
as causative of the disease. The classical approach would 
be to amplify all the exons of these genes and determine 
the nucleotide sequence of each. The alternative massive 
sequencing approach would be to purify all the putative 
genomic regions involved, and to simultaneously determine 
their nucleotide sequence in a single run.45–47 Two methods 
are generally used for the purification of the candidate 
DNA regions. The first is their amplification by polymerase 
chain reactions using a set of specific oligonucleotides as 
primers. The second method consists of fragmentation of 
the sample’s DNA and the purification of the relevant frag-
ments by hybridization to specific oligonucleotides, either in 
solution or fixed to a solid support, as previously described 
for exons’ purification.48 The selected regions can contain 
protein-coding exons and also other DNA regions, such as 
transcription regulatory regions. These regions usually cor-
respond to a few hundred genes and, therefore, the analysis 
of the sequence data generated is much easier than in other 
massive sequencing approaches. The main limitation is that 
this is a hypothesis-driven approach that does not allow 
for the detection of mutations in genes not previously related 
to the studied disease (Table 4).
Examples of the clinical use  
of exome sequencing
The most common use of exome sequencing is probably for 
the diagnosis of monogenic diseases. Over 3,000  monogenic 
disorders have been described, although the molecular genetic 
causes of most of them are still unknown.1 Exome sequencing 
can be used to identify these mutations, as discussed by 
Kuhlenbäumer et al1 in a recent review. In some of the first 
studies, exome sequencing was used to identify genetic muta-
tions responsible for familiar diseases such as the Kabuki’s,49 
Schinzel–Giedion,50 Joubert,51 and hyperphosphatasia mental 
retardation syndromes,52 severe brain malformations,53 or 
familiar amyotrophic lateral sclerosis.54 Exome sequenc-
ing has also been used to discover novel mutations present 
in a sporadic case of mental retardation.29 In addition, this 
technique has been used for the diagnosis, for example, of 
congenital chloride diarrhea,55 inflammatory bowel disease,56 
Charcot–Marie–Tooth disease,57 neonatal diabetes mellitus,58 
or the Brown–Vialetto–van Laere syndrome.59 The study 
reported by Worthey et al56 represents a relevant example of 
the clinical application of exome sequencing. A male child 
presented with a Crohn’s disease-like illness without a defini-
tive diagnosis, despite a comprehensive clinical evaluation. 
The authors decided to use an exome  sequencing approach to 
identify the causative mutation(s). Analysis of the sequence 
data detected 16,124 variants in the patient. Filtering the data 
while considering novel variants present in homozygosity, 
hemizygosity, or compound heterozygosity, and while affect-
ing highly conserved amino acid residues predicted to be 
damaging to protein function, allowed the authors to select a 
mutation in the X-linked inhibitor of apoptosis gene (XIAP). 
Functional studies demonstrated the relevance of this muta-
tion in the proinflammatory response observed in the patient. 
Based on the identification of this mutation, an allogenic 
hematopoietic progenitor transplant of cells was performed. 
Therefore, exome sequencing allowed for the identification of 
an uncharacterized mutation to make a molecular diagnosis 
for an individual patient, in the setting of a novel disease, 
which resulted in a management plan. The use of exome 
sequencing in the discovery of new causative mutations and 
in diagnosis has been recently reviewed.60,61
The study of common and complex diseases has also 
been approached through exome sequencing. Genome-wide 
 association studies have shown that some genetic variants 
 confer risk for a number of diseases. Well characterized exam-
ples are apolipoprotein E in Alzheimer’s disease,  complement 
 factor H in macular degeneration, or glucocerebrosidase/
leucine rich repeat kinase 2 in  Parkinson’s disease.62–64 The 
Advances in Genomics and Genetics 2014:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
24
Sastre
possible use of exome sequencing for the study of complex 
diseases has been discussed.2,28 One limitation of the use 
of exome sequencing in these studies is that most of the 
phenotype-associated variants lie distal to protein-coding 
regions, which would make whole-genome sequencing a bet-
ter approach.32 Some of these genetic variants can affect the 
functionality of transcription regulatory regions that control 
gene expression. The ENCODE project31,65 has performed 
a genome-wide analyses of these regulatory regions, and it 
was found that several genetic variants in specific regions of 
chromosome 5 (for example) are binding sites for the tran-
scription factor, GATA2, which are strongly associated with 
Crohn’s disease and other inflammatory diseases.
Cancers are diseases caused by the accumulation of 
genomic changes that result in the alteration of multiple 
biological processes.19 In contrast to the monogenic genetic 
alterations discussed earlier, most cancer driver mutations 
are not present in the normal tissue of the patient; a large 
 proportion of these mutations resides in protein-coding 
regions and can be detected by exome sequencing.19 How-
ever, another important group of genetic alterations are large 
genomic reorganizations such as deletions, inversions, or 
translocations that cannot be detected by exome sequencing.66 
Despite this limitation, exome sequencing has been applied 
to the discovery of cancer driver genes using two general 
strategies: the comparison of the exome of the tumors to that 
of healthy tissues from the same patient; or the comparison 
of a number of unrelated patients’ exomes to that of a similar 
number of healthy controls.67–70 Currently, extensive stud-
ies are being carried out that involve the exome or genome 
sequencing of a large cohort of cancer patients and controls 
to identify all the cancer driver genes.19,71,72 The 5,000 cancer 
genomes project is one example,73 as it aims to sequence the 
genome of 50 of the most common cancer types. The available 
data have already provided a general genomic landscape of the 
more common cancers, as reviewed by Vogelstein et al.3 About 
140 genes have been identified that promote tumorigenesis 
when altered, and this can be found in the previously men-
tioned COSMIC database.3 Detecting the mutation of one 
of these genes in the exome of a cancer sample can be an 
important step towards the proper diagnosis and treatment 
of the patient. Present data also give an idea of the complex-
ity of the cancer genome.3 Common solid tumors present an 
average number of 33 to 66 nonsilent somatic mutations.3 This 
number increases to over 200 in tumors induced by mutagenic 
agents, such as lung cancer and melanoma, and even to more 
than 1,000 in tumors deficient in DNA repair mechanisms or 
in the DNA polymerase E.3 In contrast, liquid and pediatric 
tumors present with less than ten somatic mutations.3 An 
important characteristic of tumors is that they evolve quickly 
and become heterogeneous, so that different mutations can be 
found in samples from the same patient collected in different 
regions or in different periods of time along the treatment, as 
recently shown by exome sequencing.74,75 Despite this com-
plexity, some unifying concepts are emerging, and most of the 
known cancer driver genes participate in one or more of the 
12 pathways that regulate cell survival, cell fate, and genome 
maintenance.3,19 In this scenario, exome sequencing is begin-
ning to be used for cancer diagnosis through the identification 
of driver mutations, for example, in prostate cancer.76
Exome sequencing can also be useful for cancer 
 treatment. The presence of some gene mutations can confer 
sensitivity or resistance to a given drug, which has been 
named  pharmacogenomics. For example, the use of protein 
tyrosine kinase inhibitors in cancers that overexpress the 
Abelson murine leukemia viral oncogene homolog 1 (ABL) 
or  epidermal growth factor receptor (EGFR) proteins has 
been known for several years. However, exome and genome 
sequencing approaches are revealing many more mutation 
responses to treatment associations (as highlighted in one 
review77). An informative example is the recent publica-
tion of the exome of the NCI-60 panel of cells.78 This panel 
 contains 60 well-characterized cell lines from nine cancer 
types and has been used in a broad range of biological and 
pharmacological studies.79 The nucleotide sequence of the 
exome of these cells was determined to establish the cancer 
driver genes mutated in each of them. In addition to providing 
a list of putative novel cancer driver genes, the authors studied 
the possible correlation between the genotype of each cell line 
and the previously determined response to a large number of 
anticancer agents. A correlation was found between specific 
gene mutations and the response to several drugs, revealing 
the possible importance of exome sequencing in the selection 
of a personalized treatment. Exome sequencing can also be 
used to predict cancer predisposition. Some examples can be 
found in a recent review centered on colorectal cancer and 
using whole-genome sequencing.72
Medical challenges  
of exome sequencing
Exome sequencing promises significant improvements in 
patients’ diagnoses, prognoses, and personalized treatments. 
However, the extensive application of this technology still 
requires a number of improvements, as well as the defini-
tion of important ethical and medical considerations, as 
has been discussed in recent reviews.23,27,60,61,71,77 Technical 
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challenges include the development of more efficient tech-
niques of exon capture, sequencing, and alignment to obtain 
a complete and even representation of all the exons in the 
sequence. Improvements in the data analysis software tools 
for quick and accurate detection of pathological variants are 
also needed. Extensive exome sequencing will require the 
implementation of specialized equipment and hiring teams of 
specialists with adequate expertise to generate the sequences 
and to analyze and interpret the data obtained.
The use of exome sequencing for diagnosis will also 
require the implementation of technical guidelines and 
regulations. Parameters such as the sequencing depth, exon 
coverage, quality metrics for nucleotide sequence data, or 
alignment calling will have to be normalized. Data storage 
should also be regulated.
There are also a number of complex ethical issues. An 
important issue is related to the information that should be 
provided to the patient. Exome sequencing might detect 
genetic variations that are not related to the disease under 
diagnosis. The patient might present with genetic variants that 
represent risk factors or might be causative of other diseases. 
What information should be returned to the patient? What 
would be the evidence required to consider a genetic variant 
linked to a disease? The ownership, access, and storage of 
the data are other relevant issues. Should the data generated 
be kept for possible future use during the patient’s lifetime? 
These and other ethical considerations will probably raise 
considerable controversy80 and will require extensive dis-
cussion to reach an agreement on the criteria to be used in 
clinical practice.
Conclusion
Exome sequencing is already a powerful tool used to 
 determine the molecular basis of genetic diseases. The depth 
of the genetic analysis is less than that of whole-genome 
sequencing since genetic variations in nonprotein-coding 
regions are not detected. However, the reduced number 
of sequences and sequence-analyses required for exome 
sequencing makes it a more affordable approach in clinical 
practice. Therefore, exome sequencing will probably be the 
technique of choice for the initial analysis of patients, at least 
until the price of whole-genome sequencing decreases and 
the considerable data analysis procedure is improved. An 
important limitation of the application of exome  sequencing 
in clinical practice is that the functional significance of 
most of the expected genetic variants is still unknown. This 
situation is quickly changing, as an increasing number of 
disease-associated genetic variants are determined and 
made available in public databases. It is plausible that in a 
few years, most of the genetic variations related to the risk 
of acquiring a disease, with precise molecular diagnostics, 
a prediction of the disease evolution, and a pharmacologi-
cal response, will be known. The precise knowledge of the 
patient’s exome, or genome, will then be a determining factor 
in medical practice.
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